# GluBio Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glubio-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: China
- Total disclosed funding: $50M
- Latest round: Series A (Feb 28, 2022)
- Investors on record: 7

## About

Based in China, and founded in 2021, GluBio Pharmaceutical operates as the developer of a molecular glue-targeted protein degradation drug discovery platform. In February 2022, GluBio Pharmaceutical raised USD 50 million in Series A funding from investors.

The company focuses on protein degradation targeted by molecular glue and offers a multi-dimensional protein degradation screening technology, a target validation platform, a molecular glue rational design platform, and a proprietary library of highly active compounds.

The company plans to use the Series A funds to work on molecular glue degraders, Brii, Lingyi Med, Huadong.

## Funding rounds

- Series A, Feb 28, 2022, $50M — Legend Capital, Qiming Venture Partners, Lilly Asia Ventures, Kaitai Capital, K2VC, GL Ventures, E-Fund

## Investors

- Legend Capital — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series A
- K2VC (https://capitalatlas.ai/funds/k2vc) — Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A
- E-Fund — Series A